4 October 2024
La Vie closes €25 million fundraising round
Watch the replay of Good Morning Business, on BFM Business with interviews with Nicolas Schweitzer, co-founder of La Vie ™, a company in our HFL portfolio, interviewed by...
Life Sciences
24 September 2024
Sequentia Biotech Secures €10million Equity Investment from Seventure Partners and the EIC Fund to Boost Bioinformatic Solutions for Clinical, Industrial and Research Applications
Sequentia Biotech, a #deeptech and leading bioinformatics company focused on the analysis and application of omics data, announces a €10million Series A, led by Seventure...
27 August 2024
Microbiotica’s Microbiome Medicines in Melanoma and Ulcerative Colitis Gain Regulatory Approvals in EU and UK for Phase 1b Studies
Microbiotica’s Microbiome Medicines in Melanoma and Ulcerative Colitis Gain Regulatory Approvals in EU and UK for Phase 1b Studies
Company Secures Additional Financing...
21 August 2024
Biotech: why Singapore’s Allozymes is setting up its European subsidiary in Toulouse
Allozymes, a leading innovator in the discovery and engineering of enzymes (proteins acting as catalysts in all living organisms) for the food and chemical industries, has...
5 August 2024
Fierce Biotech Names Tubulis a “Fierce 15” Biotech Company of 2024
Tubulis announced today that Fierce Biotech has named the company as one of 2024’s “Fierce 15” biotechnology companies. The annual special report features the most...
31 July 2024
CITRYLL ANNOUNCES COMPLETION OF PATIENT ENROLMENT AND DOSING IN THE REPEAT DOSING STAGE OF THE PHASE 1 TRIAL FOR THE NOVEL ANTI-INFLAMMATORY DRUG, CIT-013
Citryll, a clinical-stage biotech company developing first-in-class therapeutics to treat immune-mediated inflammatory diseases, today announces the successful completion of...
18 June 2024
Bioscience relies on the microbiota of agricultural soils to restore them!
Source : La Gazette du LABORATOIRE
©LaGazetteDuLABORATOIRE
Starfish Bioscience aims to provide microbiological solutions to restore the soil microbiome for...
14 May 2024
MaaT Pharma Launches a Global Offering of approximately 18 Million Euros
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotech company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to...
8 April 2024
MaaT Pharma Presents Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotech company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to...
15 March 2024
Siolta Therapeutics Raises $12 Million in Series C Financing for Clinical Development
The company, has announced the completion of a $12 million Series C financing round. The round, co-led by SymBiosis and Khosla Ventures, reflects enthusiasm for Siolta's...